布林佐胺联合曲伏前列素治疗原发性开角型青光眼的临床疗效和安全性

Clinical efficacy and safety of brinzolamide combined with travoprostin primary open-angle glaucoma

目的 探讨布林佐胺联合曲伏前列素治疗原发性开角型青光眼的临床疗效和安全性。方法 选取2015年3月~2016年3月丽水市人民医院收治的112例（140眼）开角型青光眼患者,将其按照随机数字法随机分为A组和B组,每组56例（70眼）,A组给予曲伏前列素进行治疗,B组给予曲伏前列素联合布林佐胺进行治疗,观察并比较2组治疗后的临床疗效并评价治疗期间2组的不良反应。结果 用药2 w、1个月、3个月、6个月后2组眼压均显著低于用药前,差异有统计学意义（P〈0.05）,但B组用药2 w、1个月、3个月、6个月后眼压均显著低于A组,差异有统计学意义（P〈0.05）。治疗后,2组BUT及ST均较用药前显著降低,差异有统计学意义（P〈0.05）,但2组用药后BUT及ST比较差异无统计学意义;2组角膜荧光素染色及眼表虎红染色评分均较用药前显著升高,差异有统计学意义（P〈0.05）,但2组用药后角膜荧光素染色及眼表虎红染色评分比较差异无统计学意义。2组不良反应发生率比较差异无统计学意义。结论 布林佐胺联合曲伏前列素治疗可降低原发性开角型青光眼患者的眼内压,但可降低泪膜稳定性,损伤角膜、结膜,减少泪液分泌,与单用曲伏前列素相当。

Objective To investigate the clinical efficacy and safety of brinzolamide combined with travoprost in the treatment of primary open- angle glaucoma. Methods 112 cases （140 e y e s ） of open-angle glaucoma patients from March 2015 to March 2016 were selected a n d r a n d o m l y d i v i d e d into the group A and the group B 56 cases （70 e y e s ） in each g r o u p . The group A was treated w i t h travoprost t h e r a p y , w h i l e the group B was g i v e n travoprost combined with brinzolamide treatment, the adverse reactions and clinical curative effects in the two groups were observed and compared during treatment. Results After two weeks, one months, three months and six months in the two groups intraocular pressure were significantly lower than those before treatment, the difference was statistically significant （ P 〈 0. 05 ） , b u t in t w o weeks, o n e months, t hree m o n t h s a n d six m o n t h s in the g r o u p B the intraocular pressure was significantly lower than that in the group A, the difference was statistically significant （P 〈 0. 05）. A f t e r t r e a t m e n t , t w o g r o u p s of BUT and ST were decreased significantly lower than before treatment, the difference was statistically significant （ P 〈 0. 05 ） , b u t t h ere w a s n o significant difference between BUT and ST after treatment, two groups of corneal fluorescein staining and ocular; B e n g a l staining s c o r e s w e r e all significantly higher than before treatment, the difference was statistically significant （ P 〈 0. 05 ） , h o w e v e r , t h ere w a s n o significant difference in c o m e a l fluorescein staining and ocular surface of rose bengal staining between the two groups. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion B r i n z o l a m i d e combined w i t h travoprost can reduce the i n traocular p r e s s u r e of patients w i t h pri m a r y open- angle glaucoma, but can reduce tear film stability, damage the cornea, conjunctiva, reduce tear secretion, there is some damage to the conjunctiva, cornea, similar with travoprost.